Proapoptotic regimes for HTLV-I-transformed cells: targeting Tax and the NF-kappaB pathway.
Kfoury
Y
Y
Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.
Nasr
R
R
Hermine
O
O
de Thé
H
H
Bazarbachi
A
A
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage; D017209:Apoptosis / Q000276:immunology; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage; D016503:Drug Delivery Systems; D005786:Gene Expression Regulation; D016356:Gene Products, tax / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D015368:Human T-lymphotropic virus 1 / Q000276:immunology / Q000378:metabolism / Q000472:pathogenicity*; D006801:Humans; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy* / Q000276:immunology; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000276:immunology* / Q000378:metabolism; D009570:Nitriles / Q000008:administration & dosage; D010087:Oxides / Q000008:administration & dosage; D061988:Proteasome Inhibitors; D013450:Sulfones / Q000008:administration & dosage; D013601:T-Lymphocytes / Q000276:immunology / Q000821:virology*
C434003:3-(4-methylphenylsulfonyl)-2-propenenitrile; D000970:Antineoplastic Agents; D001152:Arsenicals; D016356:Gene Products, tax; D016328:NF-kappa B; D009570:Nitriles; D010087:Oxides; D061988:Proteasome Inhibitors; D013450:Sulfones; D000077237:Arsenic Trioxide